A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

NCT06769152 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer
Ovarian Cancer

Interventions

DRUG: HLX43

Sponsor

Shanghai Henlius Biotech